29 May 2015 - Biopharmaceutical company Catalyst Pharmaceuticals (NasdaqCM:CPRX) revealed on Thursday the election of Richard J. Daly as its interim chief commercial officer.Daly, who is a member of the company's board of directors, will oversee its pre-commercial activities for Firdapse, replacing its outgoing CCO David Muth.Recently, Daly has served as president of US Diabetes for the joint alliance between Bristol-Myers Squibb and AstraZeneca.Previously, Daly was a founding partner and board member of SagePath Partners as well as executive vice president with P&L responsibility for businesses across the US, Canada and Central/South America at Takeda Pharmaceuticals.